Your browser is no longer supported. Please, upgrade your browser.
Settings
TLSA [NASD]
Tiziana Life Sciences PLC
Index- P/E- EPS (ttm)-0.15 Insider Own- Shs Outstand97.31M Perf Week-7.45%
Market Cap229.64M Forward P/E- EPS next Y- Insider Trans- Shs Float34.93M Perf Month-25.08%
Income- PEG- EPS next Q- Inst Own6.64% Short Float0.21% Perf Quarter-42.58%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.18 Perf Half Y-31.40%
Book/sh0.07 P/B35.76 EPS next Y- ROA- Target Price- Perf Year47.87%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.44 - 12.17 Perf YTD16.83%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.61% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low63.43% ATR0.19
Employees8 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)37.57 Volatility6.99% 7.17%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.72 Prev Close2.42
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume413.16K Price2.36
Recom2.00 SMA20-7.31% SMA50-14.75% SMA200-29.38% Volume297,088 Change-2.48%
Dec-22-20Initiated B. Riley Securities Buy $8
Dec-17-18Initiated Laidlaw Buy
May-07-21 02:00AM  
May-05-21 02:00AM  
Apr-30-21 12:00AM  
Apr-27-21 02:00AM  
Apr-14-21 05:00AM  
Apr-13-21 07:00AM  
Apr-12-21 06:07AM  
Mar-30-21 08:00AM  
07:35AM  
05:01AM  
02:00AM  
Mar-29-21 08:30AM  
02:00AM  
Mar-17-21 04:03PM  
Feb-26-21 02:00AM  
Feb-18-21 07:00AM  
Feb-16-21 10:02AM  
Feb-05-21 02:00AM  
Feb-03-21 10:11AM  
02:00AM  
Feb-02-21 05:55AM  
04:57AM  
04:15AM  
02:00AM  
Jan-27-21 02:00AM  
Jan-20-21 06:31AM  
02:00AM  
Jan-13-21 02:00AM  
Jan-11-21 12:08PM  
09:48AM  
Jan-04-21 02:00AM  
Dec-18-20 06:38AM  
Dec-17-20 10:04AM  
Dec-14-20 10:28PM  
Dec-01-20 02:00AM  
Nov-18-20 10:16AM  
Nov-11-20 02:00AM  
Nov-02-20 03:31AM  
02:00AM  
Oct-27-20 12:00PM  
Oct-22-20 07:28AM  
Oct-02-20 07:00AM  
Sep-25-20 02:00AM  
Sep-21-20 09:51AM  
Sep-17-20 02:00AM  
Sep-16-20 10:10AM  
06:00AM  
02:00AM  
Aug-28-20 05:30AM  
Aug-27-20 02:00AM  
Aug-24-20 08:42AM  
03:14AM  
02:00AM  
Aug-21-20 02:00AM  
Aug-20-20 02:00AM  
Aug-18-20 06:08AM  
02:00AM  
Aug-11-20 04:00AM  
Aug-06-20 03:57PM  
Aug-05-20 11:00AM  
Aug-04-20 02:00AM  
Aug-03-20 02:00AM  
Jul-31-20 12:05PM  
12:00PM  
02:00AM  
Jul-30-20 11:31AM  
02:00AM  
Jul-24-20 02:00AM  
Jul-20-20 10:17AM  
Jul-16-20 07:23AM  
02:00AM  
Jul-15-20 06:34PM  
04:47PM  
11:56AM  
08:28AM  
Jul-14-20 10:41AM  
Jul-10-20 01:41PM  
Jun-30-20 09:35AM  
Jun-29-20 03:12AM  
Jun-19-20 07:41AM  
02:00AM  
Jun-18-20 01:50PM  
Jun-15-20 09:53AM  
Jun-04-20 02:00AM  
May-29-20 02:00AM  
May-22-20 02:00AM  
May-14-20 10:00AM  
02:00AM  
May-11-20 02:00AM  
May-03-20 04:37AM  
Apr-27-20 09:21AM  
Apr-24-20 02:18PM  
Apr-09-20 02:00AM  
Mar-16-20 03:15PM  
Mar-12-20 10:07AM  
Mar-11-20 07:34PM  
08:09AM  
07:34AM  
Jan-21-20 12:06PM  
Jan-16-20 06:56AM  
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.